Back

A novel serum biomarker molecule for heart failure progression： VDAC3 protects against heart failure by aediating SLC25A11 stability and repairing ATP synthesis

29 August 2026 (11:09 - 11:21)
Organised by: Logo
Congress Presentation Part of: Translational, genetic, and precision medicine approaches Cardiac Hypertrophy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Chenghui Yan

(China)

4 More presentations in this session

Presentation thumbnail
Functional characterisation of AI-prioritised sarcomeric variants in hypertrophic cardiomyopathy using iPSC-derived cardiomyocytes
Doctor I. Balakrishnan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Cardiac in vivo correction of the PLN R14del cardiomyopathy mutation using prime editing
Doctor V. Rajendran (Munich, DE)
Abstract Slides Video
Presentation thumbnail
A DNA damage checkpoint drives phenotypic transition in cardiomyopathy
Doctor J. Komuro (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
Long-term clinical outcomes in a large-scale ventricular septal defect cohort: impact of anatomical subtype and intervention timing
Doctor S. Goo (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Translational, genetic, and precision medicine approaches
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 11:09 CET
You may be interested in
thumbnail
Congress Presentation
IP3R1/GRP75/VDAC1 complex mediated endoplasmic reticulum stress-mitochondrial oxidative stress in diabetic atrial remodeling
24 April 2021
thumbnail
Congress Presentation
A proteo-genomic discovery approach to identify markers of early heart failure
1 September 2025
thumbnail
Congress Presentation
Determinants of left ventricular ATP availability measured in vivo and ex vivo in patients with severe aortic stenosis: correlation of creatine kinase activity with LVEF and ATP diffusion distance
1 September 2019
thumbnail
Congress Presentation
Proline dehydrogenase (PRODH) as a metabolic target in cardiac health
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources